Patent US4623641A successfully refreshed from Google Patents.
US4623641A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of treating ulcers and erosions in the gastrointestinal system using PGI2 -methyl ester-beta cyclodextrin inclusion complexes
Assignee: Chinoin Private Co Ltd
•
Filing: 1985-09-09
•
Granted: 1986-11-18
•
Expires: 2005-09-09
Abstract
Abstract A new method is disclosed for the treatment and prevention of gastrointestinal ulcers or erosions which comprises the administration of a pharmaceutically effective amount of a PGI 2 methyl ester-beta cyclodextrin complex to a patient in need of said treatment wherein the amount of the PGI 2 methyl ester constitutes 1 to 15% by weight of the complex.
Inventors
- 👤 Jozsef Szejtli
- 👤 Magdolna Szejtli nee Rengei
- 👤 Gyorgy Cseh
- 👤 Istvan Stadler
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 18:19
CPC Classifications
A; A61; A61K; A61K47/00; A61K47/50; A61K47/69; A61K47/6949; A61K47/6951; A61K31/00; A61K31/557; A61K31/70; A61K31/715; B; B82; B82Y; B82Y5/00
Claims Analysis
Total Claims: 17
Claim 1
Independent Claim
48 words
A method of treating an ulcer in a patient which comprises the step of orally administering to said patient a pharmaceutically effective amount of a PGI 2 -methyl ester-beta-cyclodextrin complex wherein the amount of the PGI 2 -methyl ester constitutes 1 to 15% by weight of the complex.
Claim 2
Independent Claim
48 words
A method of treating an ulcer in a patient which comprises the step of orally administering to said patient a pharmaceutically effective amount of a PGI 2 -methyl ester-beta-cyclodextrin complex wherein the amount of the PGI 2 -methyl ester constitutes 1 to 15% by weight of the complex.
Claim 3
Dependent Claim
22 words
The method defined in claim 1 wherein a pharmaceutically acceptable inert carrier is combined with the PGI 2 methyl ester-beta cyclodextrin complex.
Claim 4
Dependent Claim
20 words
The method defined in claim 1 wherein the PGI 2 methyl ester-beta cyclodextrin complex is administered to treat peptic ulcers.
Claim 5
Dependent Claim
23 words
The method defined in claim 1 wherein the PGI 2 methyl ester-beta cyclodextrin complex is administered to the patient to treat stress ulcers.
Claim 6
Dependent Claim
27 words
The method defined in claim 1 wherein the PGI 2 methyl ester-beta cyclodextrin complex is administered simultaneously with or subsequent to administration of a non-steroidal antiphlogistic agent.
Claim 7
Dependent Claim
13 words
The method defined in claim 7 wherein the non-steroidal antiphlogistic agent is indomethacin.
Claim 8
Dependent Claim
72 words
In an antiphlogistic method of treatment wherein a non-steroidal antiphlogistic agent is administered to a patient in need of said treatment, the improvement which comprises the oral administration of a pharmaceutically effective amount of PGI 2 methyl ester-beta cyclodextrin complex simultaneously to or subsequently to the administration of the non-steroidal antiphlogistic agent, wherein the amount of the PGI 2 methyl ester-beta cyclodextrin complex constitutes 1 to 15% by weight of the complex.
Claim 9
Dependent Claim
72 words
In an antiphlogistic method of treatment wherein a non-steroidal antiphlogistic agent is administered to a patient in need of said treatment, the improvement which comprises the oral administration of a pharmaceutically effective amount of PGI 2 methyl ester-beta cyclodextrin complex simultaneously to or subsequently to the administration of the non-steroidal antiphlogistic agent, wherein the amount of the PGI 2 methyl ester-beta cyclodextrin complex constitutes 1 to 15% by weight of the complex.
Claim 10
Dependent Claim
14 words
An antiphlogistic composition suitable for oral administration having reduced ulcerogenic side effects which comprises:
Claim 11
Dependent Claim
14 words
An antiphlogistic composition suitable for oral administration having reduced ulcerogenic side effects which comprises:
Claim 12
Dependent Claim
11 words
(a) a pharmaceutically effective amount of a non-steroidal antiphlogistic agent, and
Claim 13
Dependent Claim
11 words
(a) a pharmaceutically effective amount of a non-steroidal antiphlogistic agent, and
Claim 14
Dependent Claim
21 words
(b) a pharmaceutically effective amount of a PGI 2 methyl ester-beta cyclodextrin complex, optionally along with a pharmaceutically acceptable inert carrier.
Claim 15
Dependent Claim
21 words
(b) a pharmaceutically effective amount of a PGI 2 methyl ester-beta cyclodextrin complex, optionally along with a pharmaceutically acceptable inert carrier.
Claim 16
Independent Claim
52 words
A method of preventing formation of an ulcer in a patient which comprises the step of orally administering to said patient a pharmaceutically effective amount of PGI 2 methyl ester-beta cyclodextrin complex wherein the amount of the PGI 2 methyl ester-beta cyclodextrin complex constitutes 1 to 15% by weight of the complex.
Claim 17
Independent Claim
52 words
A method of preventing formation of an ulcer in a patient which comprises the step of orally administering to said patient a pharmaceutically effective amount of PGI 2 methyl ester-beta cyclodextrin complex wherein the amount of the PGI 2 methyl ester-beta cyclodextrin complex constitutes 1 to 15% by weight of the complex.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1989-11-17 | 1990-05-19 | 1990-11-18 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1993-11-17 | 1994-05-19 | 1994-11-18 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1997-11-17 | 1998-05-19 | 1998-11-18 | $7700.00 | Window Closed / Lapsed |